Ezogabine (retigabine)

Carl Stafstrom, Seden Grippon, Peter Kirkpatrick

Research output: Contribution to journalArticle

Abstract

Ezogabine (Potiga; Valeant Pharmaceuticals/GlaxoSmithKline), a potassium channel opener, was approved in June 2011 by the US Food and Drug Administration (FDA) for the adjunctive treatment of partial-onset seizures in adult patients. The same drug was granted marketing authorization for this indication in the European Union in March 2011, where it is known as retigabine (Trobalt).

Original languageEnglish (US)
Pages (from-to)729-730
Number of pages2
JournalNature Reviews Drug Discovery
Volume10
Issue number10
DOIs
StatePublished - Oct 2011
Externally publishedYes

Fingerprint

Potassium Channels
European Union
United States Food and Drug Administration
Marketing
Pharmaceutical Preparations
Seizures
ezogabine
Therapeutics

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Ezogabine (retigabine). / Stafstrom, Carl; Grippon, Seden; Kirkpatrick, Peter.

In: Nature Reviews Drug Discovery, Vol. 10, No. 10, 10.2011, p. 729-730.

Research output: Contribution to journalArticle

Stafstrom, C, Grippon, S & Kirkpatrick, P 2011, 'Ezogabine (retigabine)', Nature Reviews Drug Discovery, vol. 10, no. 10, pp. 729-730. https://doi.org/10.1038/nrd3561
Stafstrom, Carl ; Grippon, Seden ; Kirkpatrick, Peter. / Ezogabine (retigabine). In: Nature Reviews Drug Discovery. 2011 ; Vol. 10, No. 10. pp. 729-730.
@article{01433719011f4602b2f363b10fb2dbf4,
title = "Ezogabine (retigabine)",
abstract = "Ezogabine (Potiga; Valeant Pharmaceuticals/GlaxoSmithKline), a potassium channel opener, was approved in June 2011 by the US Food and Drug Administration (FDA) for the adjunctive treatment of partial-onset seizures in adult patients. The same drug was granted marketing authorization for this indication in the European Union in March 2011, where it is known as retigabine (Trobalt).",
author = "Carl Stafstrom and Seden Grippon and Peter Kirkpatrick",
year = "2011",
month = "10",
doi = "10.1038/nrd3561",
language = "English (US)",
volume = "10",
pages = "729--730",
journal = "Nature Reviews Drug Discovery",
issn = "1474-1776",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Ezogabine (retigabine)

AU - Stafstrom, Carl

AU - Grippon, Seden

AU - Kirkpatrick, Peter

PY - 2011/10

Y1 - 2011/10

N2 - Ezogabine (Potiga; Valeant Pharmaceuticals/GlaxoSmithKline), a potassium channel opener, was approved in June 2011 by the US Food and Drug Administration (FDA) for the adjunctive treatment of partial-onset seizures in adult patients. The same drug was granted marketing authorization for this indication in the European Union in March 2011, where it is known as retigabine (Trobalt).

AB - Ezogabine (Potiga; Valeant Pharmaceuticals/GlaxoSmithKline), a potassium channel opener, was approved in June 2011 by the US Food and Drug Administration (FDA) for the adjunctive treatment of partial-onset seizures in adult patients. The same drug was granted marketing authorization for this indication in the European Union in March 2011, where it is known as retigabine (Trobalt).

UR - http://www.scopus.com/inward/record.url?scp=80053558884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053558884&partnerID=8YFLogxK

U2 - 10.1038/nrd3561

DO - 10.1038/nrd3561

M3 - Article

C2 - 21959281

AN - SCOPUS:80053558884

VL - 10

SP - 729

EP - 730

JO - Nature Reviews Drug Discovery

JF - Nature Reviews Drug Discovery

SN - 1474-1776

IS - 10

ER -